Hsbc Holdings PLC Purchases New Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• HSBC Holdings acquired 158,889 Halozyme shares worth approximately $12.4 million in the second quarter, while institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• HALO shares opened at $105.35, near their 12-month high of $109.66. Analysts maintain a “Moderate Buy” consensus, although the average price target of $91.20 is below the current share price; insiders have sold more than 64,000 shares over the past 90 days.

Hsbc Holdings PLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 158,889 shares of the biopharmaceutical company's stock, valued at approximately $12,447,000. Hsbc Holdings PLC owned approximately 0.14% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares in the last quarter. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $28,000. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $105.35 on Friday. The stock's 50 day simple moving average is $87.01 and its 200 day simple moving average is $74.78. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66. The stock has a market capitalization of $11.96 billion, a PE ratio of 31.45, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter last year, the company earned $1.54 EPS. The company's quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 64,103 shares of company stock valued at $5,226,496 over the last ninety days. Insiders own 2.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HALO shares. Weiss Ratings downgraded Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, August 14th. Citizens Jmp raised their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. TD Cowen lifted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source